On November 22, 2023, Jonathan Young, the Chief Operating Officer (COO) of Akero Therapeutics, made a noteworthy move by selling 30,000 shares of the company’s stock. This transaction amounted to a substantial $440,259 and was reported in a Form 4 filing with the U.S. Securities and Exchange Commission. The sale was classified under transaction code S, indicating that it took place in the open market.
It is crucial to bear in mind that insider transactions, although significant, should not be the sole basis for making investment decisions. While a new purchase by an insider might suggest an expectation of the stock to rise, insider sells can occur for various reasons and do not necessarily indicate a belief that the stock will decline.
As per the Securities Exchange Act of 1934, insider transactions are required to be disclosed to the public through a Form 4 filing within two business days of the transaction. The filing includes specific transaction codes that provide additional insights. For instance, transaction code C signifies the conversion of an option, while transaction code A suggests that the insider might have been compelled to sell shares.
It is worth noting that at the time of the report, Akero Therapeutics shares were trading down 1.74% at $15.79. This information provides context to the insider transaction and the current market conditions surrounding the company.
To summarize, while insider transactions can offer valuable insights into a company’s performance, it is essential to consider them in conjunction with other factors when making investment decisions. A holistic approach that takes into account various aspects of the company’s financial health and market conditions is crucial for informed investing.
Akero Therapeutics, Inc.
Updated on: 07/12/2023
Debt to equity ratio: Neutral
Price to earnings ratio: Strong Sell
Price to book ratio: Strong Buy
DCF: Strong Buy
7:00 PM (UTC)
Date:07 December, 2023
|Analyst / firm||Rating|
AKRO Stock Analysis: Fluctuating Prices, Declining Earnings Growth, and Potential Impact on Investors
On November 22, 2023, AKRO stock opened at $15.76, slightly lower than its previous close of $16.08. Throughout the day, the stock fluctuated between a low of $15.50 and a high of $16.06. The trading volume for the day was 27,975 shares, significantly lower than the average volume of 1,491,053 shares over the past three months. The market capitalization of AKRO stood at $802.9 million.
In terms of earnings growth, AKRO experienced a positive growth of 0.68% in the previous year and a higher growth of 4.71% in the current year. However, the projected earnings growth for the next five years is -14.08%, indicating a potential decline in profitability. The company did not disclose its revenue growth for the last year.
In comparison to AKRO, other stocks in the health technology sector also experienced slight increases in their stock prices on November 22, 2023. Quanterix Corp (QTRX) saw a rise of 0.37, equivalent to a 1.57% increase, while Innoviva Inc (INVA) had a rise of 0.13, representing a 1.00% increase.
Looking ahead, AKRO’s next reporting date is set for March 14, 2024. The earnings per share forecast for the current quarter is -$0.74. In the previous year, AKRO reported no annual revenue, and the company incurred a net loss of -$112.0 million. AKRO operates in the pharmaceuticals: major industry and is headquartered in South San Francisco, California. Investors should closely monitor AKRO’s performance and consider the potential impact of the projected decline in earnings growth over the next five years.
Promising Stock Performance: AKRO Shows Potential for 149.05% Increase, Analysts Recommend Buying
On November 22, 2023, Akero Therapeutics Inc (AKRO) showed promising stock performance based on the information provided by CNN Money. The 12-month price forecasts from 8 analysts had a median target of $39.50, with a high estimate of $60.00 and a low estimate of $33.00. This indicates a potential increase of 149.05% from the last recorded price of $15.86.
The consensus among 9 polled investment analysts was to buy AKRO stock, and this rating has remained steady since September. This suggests that market experts have confidence in the company’s future prospects.
It is important to note that AKRO’s current quarter earnings per share stood at -$0.74, indicating a loss. However, the sales for the same period were reported as $0.00. The reporting date for these figures was March 14.
Despite the negative earnings per share, the positive outlook from analysts and the significant potential for stock price growth indicate that investors have faith in Akero Therapeutics Inc. The company may have a strong pipeline of products or potential breakthroughs in its field, which could drive future success.
Investors should consider these factors when making decisions about AKRO stock. It is always recommended to conduct thorough research and consult with a financial advisor before making any investment decisions.